Tags

Type your tag names separated by a space and hit enter

Development of sexually transmitted diseases treatment guidelines, 1993. New methods, recommendations, and research priorities. STD Treatment Guidelines Project Team and Consultants.
Sex Transm Dis. 1994 Mar-Apr; 21(2 Suppl):S96-101.ST

Abstract

To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the literature on sexually transmitted disease treatment, assembled tables of evidence, and listed key questions on therapeutic outcome: microbiologic cure, alleviation of symptoms, and prevention of sequelae and transmission. At a meeting with external experts, evidence was systematically assessed and guidelines developed. Quality of evidence for microbiologic cure was generally good for gonorrhea and chlamydia, poor for syphilis, and fair for most other diseases. Evidence on preventing sequelae and transmission was limited. The Guidelines include new recommendations for single-dose oral therapy of gonorrhea (cefixime, ciprofloxacin, and ofloxacin), chlamydia (azithromycin), and chancroid (azithromycin); outpatient therapy of pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole); and patient-applied therapy of genital warts (podofilox). Syphilis therapy did not change substantially. Several global issues that emerged during the development of the World Health Organization Recommendations for the Management of Sexually Transmitted Diseases also are discussed. This evidence-based approach clarified important treatment issues and the rationale for recommendations, and identified research priorities.

Authors+Show Affiliations

Division of STD/HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Guideline
Journal Article
Practice Guideline

Language

eng

PubMed ID

8042129

Citation

Levine, W C., et al. "Development of Sexually Transmitted Diseases Treatment Guidelines, 1993. New Methods, Recommendations, and Research Priorities. STD Treatment Guidelines Project Team and Consultants." Sexually Transmitted Diseases, vol. 21, no. 2 Suppl, 1994, pp. S96-101.
Levine WC, Berg AO, Johnson RE, et al. Development of sexually transmitted diseases treatment guidelines, 1993. New methods, recommendations, and research priorities. STD Treatment Guidelines Project Team and Consultants. Sex Transm Dis. 1994;21(2 Suppl):S96-101.
Levine, W. C., Berg, A. O., Johnson, R. E., Rolfs, R. T., Stone, K. M., Hook, E. W., Handsfield, H. H., Holmes, K. K., Islam, M. Q., & Piot, P. (1994). Development of sexually transmitted diseases treatment guidelines, 1993. New methods, recommendations, and research priorities. STD Treatment Guidelines Project Team and Consultants. Sexually Transmitted Diseases, 21(2 Suppl), S96-101.
Levine WC, et al. Development of Sexually Transmitted Diseases Treatment Guidelines, 1993. New Methods, Recommendations, and Research Priorities. STD Treatment Guidelines Project Team and Consultants. Sex Transm Dis. 1994 Mar-Apr;21(2 Suppl):S96-101. PubMed PMID: 8042129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of sexually transmitted diseases treatment guidelines, 1993. New methods, recommendations, and research priorities. STD Treatment Guidelines Project Team and Consultants. A1 - Levine,W C, AU - Berg,A O, AU - Johnson,R E, AU - Rolfs,R T, AU - Stone,K M, AU - Hook,E W,3rd AU - Handsfield,H H, AU - Holmes,K K, AU - Islam,M Q, AU - Piot,P, PY - 1994/3/1/pubmed PY - 2001/3/28/medline PY - 1994/3/1/entrez SP - S96 EP - 101 JF - Sexually transmitted diseases JO - Sex Transm Dis VL - 21 IS - 2 Suppl N2 - To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the literature on sexually transmitted disease treatment, assembled tables of evidence, and listed key questions on therapeutic outcome: microbiologic cure, alleviation of symptoms, and prevention of sequelae and transmission. At a meeting with external experts, evidence was systematically assessed and guidelines developed. Quality of evidence for microbiologic cure was generally good for gonorrhea and chlamydia, poor for syphilis, and fair for most other diseases. Evidence on preventing sequelae and transmission was limited. The Guidelines include new recommendations for single-dose oral therapy of gonorrhea (cefixime, ciprofloxacin, and ofloxacin), chlamydia (azithromycin), and chancroid (azithromycin); outpatient therapy of pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole); and patient-applied therapy of genital warts (podofilox). Syphilis therapy did not change substantially. Several global issues that emerged during the development of the World Health Organization Recommendations for the Management of Sexually Transmitted Diseases also are discussed. This evidence-based approach clarified important treatment issues and the rationale for recommendations, and identified research priorities. SN - 0148-5717 UR - https://www.unboundmedicine.com/medline/citation/8042129/Development_of_sexually_transmitted_diseases_treatment_guidelines_1993__New_methods_recommendations_and_research_priorities__STD_Treatment_Guidelines_Project_Team_and_Consultants_ L2 - https://medlineplus.gov/sexuallytransmitteddiseases.html DB - PRIME DP - Unbound Medicine ER -